Evidence mapPaperPMID 38317255Full record

Trial reportBreast cancer research : BCR2024

Low-dose acetylsalicylic acid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women.

Peter Lundberg, Annelie Abrahamsson, Johan Kihlberg, Jens Tellman, Ieva Tomkeviciene, Anette Karlsson, Maria Kristoffersen Wiberg, Marcel Warntjes, Charlotta Dabrosin

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Breast cancer research : BCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Peter LundbergDepartment of Radiation Physics and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
Annelie AbrahamssonDepartment of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, 581 85, Linköping, Sweden.
Johan KihlbergCenter for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden.
Jens TellmanDepartment of Radiation Physics and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
Ieva TomkevicieneDepartment of Radiology and Department Medical and Health Sciences, Linköping University, Linköping, Sweden.
Anette KarlssonDepartment of Radiation Physics and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
Maria Kristoffersen WibergCenter for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden.
Marcel WarntjesCenter for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden.
Charlotta DabrosinDepartment of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, 581 85, Linköping, Sweden. charlotta.dabrosin@liu.se.ORCID 0000-0001-7191-0018
Linköping University · SE

Funding

Cancerfonden 2021/1414Vetenskapsrådet 2018-02584
6 · The paper itself

Abstract

purposeOne major risk factor for breast cancer is high mammographic density. It has been estimated that dense breast tissue contributes to ~ 30% of all breast cancer. Prevention targeting dense breast tissue has the potential to improve breast cancer mortality and morbidity. Anti-estrogens, which may be associated with severe side-effects, can be used for prevention of breast cancer in women with high risk of the disease per se. However, no preventive therapy targeting dense breasts is currently available. Inflammation is a hallmark of cancer. Although the biological mechanisms involved in the increased risk of cancer in dense breasts is not yet fully understood, high mammographic density has been associated with increased inflammation. We investigated whether low-dose acetylsalicylic acid (ASA) affects local breast tissue inflammation and/or structural and dynamic changes in dense breasts.

methodsPostmenopausal women with mammographic dense breasts on their regular mammography screen were identified. A total of 53 women were randomized to receive ASA 160 mg/day or no treatment for 6 months. Magnetic resonance imaging (MRI) was performed before and after 6 months for a sophisticated and continuous measure breast density by calculating lean tissue fraction (LTF). Additionally, dynamic quantifications including tissue perfusion were performed. Microdialysis for sampling of proteins in vivo from breasts and abdominal subcutaneous fat, as a measure of systemic effects, before and after 6 months were performed. A panel of 92 inflammatory proteins were quantified in the microdialysates using proximity extension assay.

resultsAfter correction for false discovery rate, 20 of the 92 inflammatory proteins were significantly decreased in breast tissue after ASA treatment, whereas no systemic effects were detected. In the no-treatment group, protein levels were unaffected. Breast density, measured by LTF on MRI, were unaffected in both groups. ASA significantly decreased the perfusion rate. The perfusion rate correlated positively with local breast tissue concentration of VEGF.

conclusionsASA may shape the local breast tissue microenvironment into an anti-tumorigenic state. Trials investigating the effects of low-dose ASA and risk of primary breast cancer among postmenopausal women with maintained high mammographic density are warranted. Trial registration EudraCT: 2017-000317-22.

Indexed as

Breast NeoplasmsAspirinBreast DensityFemaleHumansInflammationMammographyPostmenopauseTumor MicroenvironmentAspirinInflammationMammographyMicrodialysisMRIRandomized trial

Identifiers

PMID38317255
PMCPMC10845760
OpenAlexW4391541359

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.